Rong Tao

9PUBLICATIONS
13CO-AUTHORS
Molecular targetsHaematological tumoursPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jul 13, 2026
Selinexor plus tislelizumab in patients with relapsed/refractory natural killer/T-cell lymphoma after failure of PD-1 blockade: the phase 1b TOUCH trial.

|Jul 01, 2026
Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study.

|Jun 07, 2026
Clinicopathologic spectrum and outcomes of primary ovarian lymphoma: a retrospective case series.

|Dec 20, 2024
Optimal timing and impact of allogeneic peripheral blood stem cell transplantation in adult T-cell lymphoblastic lymphoma: insights from a large cohort multi-center real-world study in Shanghai.

Fangfang Yu, Jiahua Niu, Jianmin Yang

|Aug 24, 2023
Selinexor With Anti-PD-1 Antibody as a Potentially Effective Regimen for Patients With Natural Killer/T-Cell Lymphoma Failing Prior L-Asparaginase and PD-1 Blockade.

Rong Tao, Chuanxu Liu, Wenhao Zhang

|Mar 30, 2023
Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II Study.

Huiqiang Huang, Rong Tao, Siguo Hao

Pageof 2

Frequent Collaborators

1 joint publications

Peng Liu

1 joint publications

Huiqiang Huang

1 joint publications

Hong Cen

1 joint publications

Jie Jin